➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Merck
Express Scripts
Dow
Harvard Business School

Last Updated: October 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,973,031

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,973,031 protect, and when does it expire?

Patent 7,973,031 protects RYDAPT and is included in one NDA.

This patent has thirty-four patent family members in twenty-four countries.

Summary for Patent: 7,973,031
Title:Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
Abstract: The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Inventor(s): Griffin; James Douglas (Brookline, MA), Manley; Paul William (Arlesheim, CH)
Assignee: Novartis AG (Basel, CH) Dana-Farber Cancer Institute Inc (Boston, MA)
Application Number:10/493,786
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,973,031
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,973,031

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis RYDAPT midostaurin CAPSULE;ORAL 207997-001 Apr 28, 2017 RX Yes Yes   Start Trial   Start Trial TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,973,031

PCT Information
PCT FiledOctober 29, 2002PCT Application Number:PCT/EP02/12076
PCT Publication Date:May 08, 2003PCT Publication Number: WO03/037347

International Family Members for US Patent 7,973,031

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 335490   Start Trial
Australia 2006249245   Start Trial
Brazil 0213739   Start Trial
Brazil PI0213739   Start Trial
Canada 2462657   Start Trial
China 101703509   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.